Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. | Zendy

Fabio Nicolini | Zendy; P Lee | Zendy; Gaddiel Rios | Zendy; Kandice KottkeMarchant | Zendy; Eric J. Topol | Zendy

Open Access

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.

Author(s) -

Fabio Nicolini,

P Lee,

Gaddiel Rios,

Kandice KottkeMarchant,

Eric J. Topol

Publication year - 1994

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.89.4.1802

Subject(s) - medicine , hirudin , thrombolysis , saline , fibrinogen , anesthesia , pharmacology , thrombus , fibrinolytic agent , platelet , partial thromboplastin time , antithrombotic , thrombin , myocardial infarction

We evaluated the effects of a novel platelet fibrinogen receptor antagonist, Integrelin, and a direct thrombin inhibitor, recombinant hirudin, given together with recombinant tissue plasminogen activator (rTPA) in a canine experimental model of intracoronary thrombosis. We tested the hypothesis that combination of both agents at low doses would have an additive antithrombotic effect, resulting in a significant improvement in the efficacy of rTPA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research